Enlivex Therapeutics (ENLV)

• Market cap: $27.3M
• 1 day: 5.08%
• 5 days: 3.33%
• 1 month: 27.05%
• 3 months: -17.88%
• 6 months: -6.06%
• Year to date: -62.42%
• 1 year: -36.73%
• 5 years: -87.39%
• 10 years: -99.50%

About: Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.

Employees: 49

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 1

184% more call options, than puts

Call options by funds: $71K | Put options by funds: $25K

67% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 3

30% more capital invested

Capital invested by funds: $3.31M [Q2] → $4.31M (+$1M) [Q3]

12% more funds holding

Funds holding: 17 [Q2] → 19 (+2) [Q3]

0.82% more ownership

Funds ownership: 11.16% [Q2] → 11.98% (+0.82%) [Q3]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $6 384% upside
• Avg. target: $10.67 760% upside
• High target: $13 948% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

D. Boral Capital Jason Kolbert 25% 1-year accuracy 38 / 150 met price target	948% upside $13	Buy Maintained	11 Dec 2024
HC Wainwright & Co. Raghuram Selvaraju 39% 1-year accuracy 121 / 308 met price target	384% upside $6	Buy Reiterated	27 Sept 2024
EF Hutton Jason Kolbert 25% 1-year accuracy 38 / 150 met price target	948% upside $13	Buy Maintained	26 Sept 2024